Contraceptive pipeline: 2023 outlook
In this interview, Michael Krychman, MD, a community-based gynecologist in Newport Beach, California, takes a look at 2022 advances within the contraceptive space, as well as looks toward the future.
The contraceptive landscape is ever-changing. From new long-acting reversible contraception to nonhormonal options, pharmaceutical companies and researchers alike are continuously coming up with new forms of contraception to provide every woman with not only the ability to prevent pregnancy, but also treat other nonpregnancy-related symptoms such as acne and heavy periods. In this interview, Michael Krychman, MD, a community-based gynecologist in Newport Beach, California, takes a look at 2022 advances within the contraceptive space, as well as looks toward the future.
Recap on reproductive rights with David Hackney, MD, MS
December 20th 2022In this episode of Pap Talk, we spoke with David Hackney, MD, MS, maternal-fetal medicine physician at Case Western Reserve University and chair of ACOG's Ohio chapter for a full recap of where restrictions on reproductive rights have been and where they're going.
Listen
S4E3: Myfembree for moderate-to-severe endometriosis pain: Potential for adolescents
March 2nd 2022In this episode of Pap Talk, Contemporary OB/GYN® Associate Editor Lindsey Carr sat down with Jessica Shim, MD, an attending at in the Division of Gynecology, Department of Surgery, Boston Children’s Hospital; Harvard Medical School Boston, Massachusetts, to discuss Myfembree (relugolix, estradiol, and norethindrone acetate tablets; Myovant Sciences, Pfizer) and its possible approval in May 2022.
Listen
IUD placement within 48 hours nonsuperior vs 2 to 4 weeks after abortion
November 19th 2024A study reveals no significant difference in 6-month intrauterine device use between placements within 48 hours or 2 to 4 weeks after a second-trimester abortion, though earlier placement carries a higher expulsion risk.
Read More
